A quarter century after its founding, the McGovern Institute reflects on its discoveries in the areas of neuroscience, neurotechnology, artificial intelligence, brain-body connections, and therapeutics.
FragFold, developed by MIT Biology researchers, is a computational method with potential for impact on biological research and therapeutic applications.
ReviveMed uses AI to gather large-scale data on metabolites — molecules like lipids, cholesterol, and sugar — to match patients with therapeutics.
Junior Katie Spivakovsky describes her path through New Engineering Education Transformation to biomedical research and beyond.
By sidestepping the need for costly interventions, a new method could potentially reveal gene regulatory programs, paving the way for targeted treatments.
Fifteen new faculty members join six of the school’s academic departments.
Most antibiotics target metabolically active bacteria, but with artificial intelligence, researchers can efficiently screen compounds that are lethal to dormant microbes.
MIT researchers plan to search for proteins that could be used to measure electrical activity in the brain.
Joining three teams backed by a total of $75 million, MIT researchers will tackle some of cancer’s toughest challenges.
These compounds can kill methicillin-resistant Staphylococcus aureus (MRSA), a bacterium that causes deadly infections.
